2015 hasn’t been the greatest year for the stock market. A quick glance at the major indices paints this picture; the Nasdaq (QQQ) composite has remained relatively flat, while the DJIA (DIA) and the S&P 500 (SPY) are down about 8.5% and 5.5% respectively.

Even still, there have been some spectacular performers so far this year. Not only have these stocks had great growth this year, but they also display solid Zacks Ranks and other metrics. Below we’ve compiled a list of some of the market’s best stocks so far in 2015.

1. Dynavax Technologies (DVAX – Snapshot Report)

Dynavax discovers and develops innovative products to treat and prevent allergies, infectious diseases, and inflammatory diseases. The company researches and uses versatile strategies to alter immune system responses. In July, an independent board decided to continue Dynavax’s clinical trial for its hepatitis B vaccine.

In an industry that has dropped an average of 5% year-to-date, DVAX is currently up about 68%. As the company stands poised to break into a hepatitis B vaccination market that is dominated by just two other products, many predict a bullish future for DVAX. In the past 30 days, we’ve seen three positive earnings estimate revisions. Currently, DVAX has a Zacks Rank #2 (Buy).

2. Recro Pharma Inc. (REPH – Snapshot Report)

Recro Pharma is another innovative drug maker, operating as a clinical stage specialty pharmaceutical company. The company develops non-opioid pain treatments in the post-operative setting. Currently, REPH has two late-stage pain reduction products that appear very promising and have made investors very excited about the future for this company.

REPH is both our most significant gainer and smallest cap stock on the list. With a market cap around $115 million, Recro Pharma certainly isn’t the biggest company, but a year-to-date price growth of 365% is very impressive. A Zacks Rank #2 (Buy) also highlights the strength of this stock.